Immunogenicity of adenovirus vaccines expressing the PCV2 capsid protein in pigs. Issue 36 (24th August 2017)

• Record Type: Journal Article
• Authors: Li, Delong; Du, Qian; Wu, Bin; Li, Juejun; Chang, Lingling; Zhao, Xiaomin; Huang, Yong; Tong, Dewen
• Is Part Of: Vaccine. Volume 35:Issue 36(2017)
• Page Start: 4722
• Page End: 4729
• Publication Date: 2017-08-24
• Subjects: PCV2 -- Secretory recombinant adenovirus -- Immunogenicity -- Pigs; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2017.07.031
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Ad-A-spCD40L-spCap-spGMCSF-W induced better immune response than SH-strain. Ad-A-spCD40L-spCap-spGMCSF-W induced better cellular immune response than SH-strain. Ad-A-spCD40L-spCap-spGMCSF-W provided better protective efficacy than SH-strain. Abstract: Porcine circovirus type 2 (PCV2) is the main pathogen of porcine circovirus associated disease (PCVAD), causing great economic losses in pig industry. In previous study, we constructed adenovirus vector vaccines expressing PCV2 Cap either modified with Intron A and WPRE, or CD40L and GMCSF, and evaluated all of these vaccines in mice and in pigs. Although Ad-A-C-W and Ad-CD40L-Cap-GMCSF could induce stronger immune responses than Ad-Cap, neither of them was better than commercial inactivated vaccine PCV2 SH-strain. In this study, secretory recombinant adenoviruses (Ad-A-spCap-W and Ad-A-spCD40L-spCap-spGMCSF-W) and non-secretory recombinant adenovirus Ad-A-CD40L-Cap-GMCSF-W were constructed, and identified by western blot and confocal laser microscope observation. The results of ELISA and VN showed that humoral immune responses induced by Ad-A-spCap-W and Ad-A-CD40L-Cap-GMCSF-W were not significantly different from SH-strain, but Ad-A-spCD40L-spCap-spGMCSF-W could induce significantly higher humoral immune response than SH-strain. Lymphocytes proliferative and cytokines releasing levels of Ad-A-spCap-W and Ad-A-CD40L-Cap-GMCSF-W were not significantly different from SH-strain, but Ad-A-spCD40L-spCap-spGMCSF-W was significantly higher than SH-strain. PCV2-challenge experiment showed that virus loads were significantly reduced in Ad-A-spCD40L-spCap-spGMCSF-W vaccinated group, and no obviously clinical and microscopic lesions were observed in Ad-A-spCD40L-spCap-spGMCSF-W vaccinated group. Altogether, these results demonstrate that recombinant adenovirus vaccine Ad-A-spCD40L-spCap-spGMCSF-W induces stronger immune responses and provides better protection than commercial inactivated vaccine PCV2 SH-strain, and suggest that Ad-A-spCD40L-spCap-spGMCSF-W could be a potential vaccine candidate against PCVAD.